Chapter 4: Gene Function and Protein Structure

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

It begins with a drop of blood.

Within, you know, the first 24 to 48 hours of life, almost every newborn in the world undergoes this crucial battery of tests.

Right.

They're critically gathering a few drops of blood for the newborn screen.

That blood is rushed to a lab and it's here in this quiet analysis of chemical reactions that we find the key to one of the most fundamental questions in biology.

Which is, how does our genetic blueprint actually dictate who we are, right down to the specific molecular processes that keep us alive?

Exactly.

And that newborn screen, which looks for

life altering genetic diseases like phenylketonuria or PKU.

That's probably the most visceral real world application of what we're talking about today.

It relies completely on a concept developed over decades of research.

The direct mechanistic link between a gene and a specific functioning enzyme.

Yeah.

When we talk about genetics, most people are comfortable with Mendelian inheritance.

You know, the 3 .1 ratios and 9 .3 .3 .1s.

Those tell us the pattern.

But they don't tell you how.

How does the gene actually do its job inside the cell?

We have to bridge that gap.

The gap between the abstract idea of a gene and the, well, the physical machinery of life.

So the core questions for this deep dive are really molecular.

What is the relationship between a gene and an enzyme?

How do genes control these incredibly complex biochemical pathways?

And how did figuring all of this out lead us to be able to detect and manage these diseases, sometimes just moments after birth?

What we're examining today, historically speaking, it's not just another chapter.

It's really the definitive start of molecular genetics.

We're going to trace the classic, rigorous evidence that forced science to move beyond just observing traits to understanding the gene as a molecular instruction set for building specific proteins.

That's our mission today.

To begin this journey, we have to go back to a time before we even knew the structure of DNA.

I mean, even before Mendelian genetics was fully accepted.

We start with a pioneer whose work was so far ahead of its time, it was pretty much ignored.

An English physician named Archibald Garad in the early 1900s.

And he was focused on these rare human diseases, right?

Specifically one called alcaptanuria.

Yes.

And this condition has one truly dramatic, very visual symptom.

Which is?

Affected individuals.

Their urine turns strikingly black when it's exposed to air, almost instantly.

And then later in life, they develop this really painful, debilitating arthritis.

So Garad, he works with William Bateson and they quickly figured out the inheritance pattern.

Right.

Through pedigree analysis, they saw it was a classic autosomal recessive trait.

You need two copies of the mutant allele to get the disease.

So that's the classical genetic side of things.

But Garad didn't stop there.

He was also a chemist.

And his real breakthrough was investigating the chemical reason for the black urine.

Okay.

So what did he find?

He found that normal people can completely metabolize a specific compound called homogenetic acid, or HA.

But people with alcaptanuria, they excrete massive quantities of it.

It's the HA oxidizing in the air that turns the urine black.

And this led to his big idea, the inborn error of metabolism.

It was a bold statement for the time.

He basically said this genetic disease is caused by the heritable abscess of a specific enzyme needed for one tiny step in a metabolic pathway.

So for alcaptanuria, the block step was the conversion of that homogenetic acid into the next chemical in the chain.

Exactly.

And the aha moment for Garad, which is still central to biochemistry today, was realizing that the compound just before a blocked step accumulates.

The buildup of HA pointed, like an arrow, directly to the missing enzyme.

So if I'm following, Garad was saying that the gene was responsible for making that specific enzyme.

If the gene was mutant, the enzyme failed, the pathway got jammed, and the precursor chemical just backed up.

Precisely.

He basically laid out the one gene, one enzyme hypothesis decades before anyone could prove it.

And the historical irony, as you said, is that nobody really paid attention.

Not at all.

The scientific world just wasn't ready to connect these abstract factors of heredity to the messy reality of cellular chemistry.

It took 40 years for science to catch up.

And that rigorous proof finally arrived in 1942 from George Beadle and Edward Tatum.

Their work really launched the field of biochemical genetics.

And they won a Nobel Prize for it.

But they didn't use humans.

They used orange bread mold.

Neurosporacrosis, yeah.

And you have to appreciate the elegance of using a model organism here.

So what made this mold so perfect for proving the theory?

Well, a few reasons.

It has a short life cycle, which is great.

It has very simple nutritional needs.

But the most important reason for a geneticist is that it's a haploid organism.

Let's pause on that because it's key.

We're deployed.

We have two copies of every gene, so a recessive mutation can be hidden by a normal copy.

Exactly.

But since Neurospora is haploid for most of its life, it only has one copy of each gene.

So the effect of a mutation, even a recessive one, is immediately expressed.

There's no backup copy.

It makes finding mutants incredibly efficient.

Okay, so let's quickly walk through the life cycle they used.

So for genetic analysis, you need the sexual cycle.

You take two different mating types, A and A, and bring them together.

Their cells fuse, their nuclei fuse, and you get a temporary diploid nucleus.

And that diploid nucleus immediately undergoes meiosis.

Right, which produces eight haploid spores, all neatly lined up in a little sac called an ascus.

So you can easily track how the mutant alleles segregate.

Now let's talk nutrition.

The wild type, the normal mold, is a prototroph.

A prototroph is just a self -sufficient organism.

It can grow on a minimal medium, basically just salts, a sugar, and one vitamin, biotin.

Which means it has all the functional enzymes it needs to make everything else for itself, like all 20 amino acids.

Correct.

So Betel and Tatum's goal was to create oxotrophs, nutritional mutants.

Mutants that couldn't make a necessary compound and would therefore need a supplement to grow.

They wanted to prove that breaking one gene meant you needed one specific nutrient.

And their experimental design was just revolutionary in its simplicity.

First, they zapped the asexual spores with x -rays.

To create random mutations.

Exactly.

Then, and this is a vital step, they crossed those mutated spores with a normal wild type strain to make sure any nutritional problem they found was a stable, heritable genetic mutation and not just some temporary damage from the x -rays.

Okay, so they grow the resulting spores on a complete medium.

Right, their safety net.

This rich medium has everything in it, so even if a spore has a lethal defect, it can still survive and grow.

Then comes the screen.

They take a sample from each of those cultures and test it on minimal medium.

If a strain fails to grow on minimal, they know they found an oxotroph.

A mutant.

And the final step is figuring out what's broken.

Yep.

They would systematically test that oxotroph on different supplemented media.

Minimal plus amino acids, minimal plus vitamins.

And so on.

Until they found what it needed.

If it only grew when you added, say, tryptophan, they knew they had a tryptophan oxotroph.

The gene for making tryptophan was broken.

So that gets them the raw material, the mutants.

But the real genius here is how they use these mutants to map an entire metabolic pathway.

This is where it becomes just a beautiful exercise in logic.

It really is.

Once they had a set of different mutants that all needed the same final product, let's use the methionine pathway as the example, they could use the intermediate compounds to figure out the order of the genes.

And the key principle here for the listener is what?

It's like an assembly line.

The later in the assembly line your strain is blocked, the fewer intermediate parts can rescue its growth.

If the block is early, adding the product of that blocked step lets the rest of the line keep running.

Exactly.

So let's say we have four different genes, met2, met3, met5, and met8.

A mutation in any one of them means the mold needs methionine to live.

And we know there are a few intermediate chemicals in the pathway like homocysteine and cystophenine.

Okay, so let's look at the data.

Remember, all four of these grow on methionine, but none grow on the minimal medium by itself.

Let's start with the most restricted mutant,

met8.

This strain only grows if you add methionine itself.

It doesn't grow on any of the intermediates.

The deduction seems clear.

If it can't use any of the known precursors, its block must be at the very last step.

That's it.

The conversion of homocysteine into methionine, so the met8 gene controls the enzyme for that final step.

Okay, what's next?

Next up is met2.

This one grows on methionine or homocysteine, but not on the earlier intermediates.

So the fact that homocysteine rescues it means the block must be before the step that makes homocysteine.

Correct.

The met2 block must be at the step immediately preceding homocysteine production.

All the later steps are fine.

Now for met3.

This one is more flexible.

It grows on methionine, homocysteine, or cystophine.

Okay, so if cystothionine works, it must come before homocysteine in the pathway.

And the met3 gene must control the enzyme that makes cystothionine.

You've got it.

Finally, there's met5.

This one is the most flexible of all.

It grows on everything.

Methionine and all the intermediates we tested.

Which tells us that its block is the earliest one in this sequence we're looking at.

The met5 gene must control a very early step.

By just observing which chemical rescued which mutant, we genetically dissected the entire pathway.

We established the chemical order, and we mapped four genes to four specific sequential steps.

That's the irrefutable evidence, the direct link.

Gene to enzyme to step in the pathway.

That proof was just monumental.

It established the one gene, one enzyme hypothesis.

But as molecular biology advanced, we learned that proteins are often more complex.

Yes, exactly.

What if an enzyme isn't just one single chain, but a big complex made of several different polypeptide chains?

Like some of the DNA polymerases?

Right.

If each of those chains or subunits is chemically distinct, then the blueprint for each chain has to come from a different gene.

So if your enzyme has an alpha chain and a beta chain, you need gene A for alpha and gene B for beta.

It's not one gene for the whole enzyme anymore.

Correct.

So the hypothesis was refined to the one gene, one polypeptide hypothesis.

The gene provides the instructions for a single polypeptide chain.

And it's important to note the modern exceptions too, like not all genes even code for proteins.

That's a great point.

Some genes code for functional RNA molecules, like ribosomal RNA.

And in eukaryotes, we have alternative splicing, which lets one gene produce multiple different polypeptides.

But the core principle, that a gene is a molecular instruction for a specific amino acid sequence, that remains completely sound.

And this foundational understanding of pathways isn't just history.

It's central to cutting edge research today, especially in genomics and the study of the metabolome.

The metabolome is just the complete set of all the small chemical molecules in a cell, all the intermediates and products of these pathways.

And studying it is called metabolomics.

It's like watching all those gene encoded enzymes at work in real time.

Let's apply this to a really fascinating case, the human gut microbiome.

We rely on our gut microbes to break down things we can't digest, like complex fibers.

And that process produces crucial stuff for us, the host.

Mostly short -chain fatty acids or SCFAs.

These can provide up to 10 % of our daily calories.

It's a powerful collaboration.

So researchers looked at the interaction between two key members of this gut community, a bacterium and an archaeon.

Right.

Bacteroids, the teatomicron, the bacterium,

methanobrevibacter smithii, the archaeon.

They wanted to see if they behaved differently when grown together.

And to do that, they used transcriptomics.

Which is just studying all the RNA molecules being expressed, telling you which genes are switched on.

And the evidence showed this really sophisticated collaboration.

So what happened when they were together?

The bacterium, B, the teatomicron, it ramped up its genes for breaking down fiber and boosted its production of an SCFA called acetate.

It was working harder to get us food.

And this created a byproduct.

Excess formate.

And the archaeon, M smithii, it sensed this and switched on its own formate metabolism genes, effectively cleaning up the bacterium's waste product.

So by removing the waste, the archaeon lets the bacterium work even more efficiently.

Far more efficiently.

And the biological impact for the host is huge.

We extract and absorb more calories.

But here's where it gets complicated.

Increased populations of that archaeon, M smithii, have been linked to obesity.

Which brings us right back to the gene.

Because we understand the specific genes that M smithii uses, scientists can now potentially target those genes with drugs.

So you could interfere with the archaeon's metabolism to manage the host's weight.

That's an amazing clinical application.

Moving from the gut back to human health, let's explore how these enzyme deficiencies manifest as human diseases.

Starting with the classic example,

phenylketonuria, or PKU.

PKU is an autosomal recessive mutation, usually on chromosome 12.

It affects the gene for the enzyme phenylalanine hydroxylate.

That enzyme is critical because it converts the amino acid phenylalanine into another one, tyrosine.

Right.

So if that enzyme is missing, the phenylalanine we eat, which we need for growth, can't be processed.

It builds up and the body converts the excess into phenylpyruvic acid.

And that buildup is incredibly toxic.

Profoundly neurotoxic.

If it's not treated, it causes severe irreversible damage to the developing central nervous system.

Severe mental retardation, slow growth, early death.

It's a race against time.

PKU is also a textbook case of pleiotropy, where one gene defect causes multiple effects.

That's right.

Because you can't make tyrosine, you become deficient in it.

And tyrosine is the precursor for a bunch of other vital molecules.

Like melanin, the skin pigment.

And the hormones, thyroxine, and adrenaline.

This is why PKU patients often have very fair skin, light hair, and blue eyes, regardless of their family genetics.

They also have low levels of stress hormones.

And the treatment requires this immediate and lifelong, strictly controlled, low phenylalanine diet.

It's incredibly restrictive.

And we have to mention maternal PKU.

If a woman with PKU becomes pregnant and doesn't stick to her diet, the high phenylalanine in her blood crosses the placenta and can damage the fetus's brain.

Even if the baby doesn't have the PKU genotype itself.

Exactly.

The maternal environment is key.

And the diagnosis relies on the Guthrie test.

How does that work?

It's quite elegant.

A spot of the baby's blood is put on a culture of bacteria.

The culture also contains a chemical that normally stops the bacteria from growing.

But if the baby's blood has high levels of phenylalanine, it counteracts the inhibitor and the bacteria grow.

A positive test.

Which is why people with PKU can't consume artificial sweeteners with aspartame.

It breaks down into phenylalanine.

It's effectively a poison for them.

Let's move to another pathway block.

Albinism.

The classic form is another autosomal recessive condition.

And it's caused by a mutation in the enzyme tyrosinase.

Which is part of the pathway that converts tyrosine into melanin pigment.

So if tyrosinase is broken, the pathway stalls.

No melanin gets produced.

The phenotype is obvious.

White skin and hair.

Red irises.

Extreme light sensitivity.

Now, you mentioned there's a genetic complexity here.

There is.

The melanin pathway has multiple steps.

It's controlled by multiple genes.

There are at least three different types of albinism.

Each caused by a defect in a different gene.

Which means two parents, both with albinism, could potentially have a normally pigmented child.

If their mutations are in different genes in that same pathway.

Yes,

it's a powerful illustration that the whole assembly line needs to be working.

Speaking of pleiotropy, you said there's no better example than Cartagena syndrome.

The symptoms seem totally unrelated.

They do.

Chronic sinus and lung problems.

All males are sterile.

Female fertility is reduced.

And about half the time the heart is on the right side of the chest.

Dextrocardia.

How on earth are those things connected?

The molecular cause is mutations in the genes that code for the dinin motors in our cilia and flagella.

Dinin is the protein motor that makes them move.

And if it's defective, your cilia and flagella are immobile.

They don't work.

Okay, that instantly explains the lung infections.

Cilia can't clear out bacteria.

And male sterility, the sperm's flagellum can't swim.

Exactly.

But the dextrocardia is the most amazing part.

Studies in mice showed that early in the embryo, rotating cilia on a structure called the node create a leftward fluid flow.

This flow is the signal that tells the body how to form its left and right sides.

So if there's no flow because the cilia are broken.

The placement of internal organs is randomized.

The heart ends up on the right about 50 % of the time.

It's a stunning link from a tiny molecular motor to the entire body plan.

Our last enzyme deficiency case is the devastating Tay -Sachs disease.

This is a recessive mutation on chromosome 15, tragically common in certain populations like Ashkenazi Jews.

The defect is in the HXA gene, which codes for a lysosomal enzyme, Hexay.

Lysosomes are the cell's recycling centers.

Hexay's job is to break down a specific fatty acid molecule in the brain called the GM2 ganglioside.

So if Hexay is non -functional, this GM2 ganglioside can't be broken down, it just accumulates.

Specifically in brain neurons, causing them to swell and die.

The symptoms are horrific.

Rapid neurological degeneration, paralysis, blindness, and death by age three or four.

There's no cure, which is why for Tay -Sachs, genetic counseling and carrier detection in high -risk populations are absolutely critical.

It's the most effective tool we have.

So far we've focused on enzymes, but genes build all proteins, including non -enzymatic ones.

Yes, structural proteins, transport proteins, and they're often easier to study because they're much more abundant in the cell than most enzymes.

And the definitive proof that genes control these proteins came from studying hemoglobin and sickle cell anemia.

SCA was first described in 1910.

The core problem is that under low oxygen, red blood cells lose their flexible disc shape and become rigid, crescent -shaped,

sickled.

And the consequences are awful.

They are.

The fragile cells break, causing anemia.

And their rigid shape clogs capillaries, blocking blood flow, causing excruciating pain and organ damage.

The pivotal moment came in 1949 from Linus Pauling.

He hypothesized that this had to be a molecular disease, an actual physical alteration in the hemoglobin molecule itself.

And he tested this using electrophoresis.

Right, a technique that separates molecules by their electrical charge.

When he tested normal hemoglobin HbA and sickle hemoglobin HbS, they migrated to different positions.

Proving they had a different charge, so they must be structurally different.

Exactly.

But here's the clincher.

When he tested blood from heterozygotes, people with the sickle cell trait.

What did he see?

Two distinct bands.

A perfect 1 .1 mixture of normal HbA protein and sickle HbS protein.

Wow.

So that proved the gene mutation was directly changing the chemical structure of the protein.

It was undeniable.

Then in 1956, Vernon Ingram pinpointed the exact change.

Which was?

A single amino acid substitution on the beta -globin chain.

At position number six?

Just one amino acid.

Just one.

In normal hemoglobin, it's glutamic acid, which is negatively charged and water -loving.

In sickle hemoglobin, it's replaced by valine, which is neutral and water -hating.

And that tiny change causes everything.

Everything.

Under low oxygen, that water -hating valine causes the hemoglobin molecules to stick together, trying to hide from the water.

They aggregate into long, rigid fibers that physically distort the red blood cell into that sickled shape.

It's a catastrophic self -assembly failure.

One final example of a non -enzymatic protein defect.

Cystic fibrosis, CF.

The most common lethal autosomal recessive disease among Caucasians.

Characterized by this suite of devastating symptoms, all linked to one thing.

Abnormally thick viscous mucus.

With modern treatments, life expectancy is now around 40.

But it's a profound burden.

And the CF gene was found using modern mapping on chromosome 7.

It codes for a protein called the CFTR.

The Cystic Fibrosis Transmembrane Conductance Regulator.

It's a large protein that functions as a chloride ion channel in the cell membrane.

So it controls the flow of chloride ions.

Which in turn helps regulate the movement of water.

And the most common mutation, accounting for about 70 % of cases, is called the Delta F508 mutation.

Meaning?

It's a tiny deletion of three base pairs that causes the loss of a single amino acid, phenylalanine, at position 508.

And losing that one amino acid breaks the whole channel.

It impairs the function and proper folding of the channel.

The faulty ion transport leads directly to that thick sticky mucus that defines the disease.

It's an incredibly precise molecular diagnosis.

As our molecular understanding of all these diseases expanded, the need to translate that knowledge into prevention became critical.

Which brings us to genetic counseling.

Genetic counseling is a communication process.

The goal is to analyze the probability of risk for a patient or for prospective parents.

It all starts with the oldest tool we have.

Pedigree analysis.

Studying the family history.

Right.

To establish the inheritance pattern and quantify the risk.

From there, you can move to either carrier detection or fetal analysis.

Carrier detection is about the parents.

Identifying healthy heterozygotes.

Which is crucial because if both parents are carriers for a recessive disease like Tay -Sachs, they have a 25 % chance with each pregnancy of having an affected child.

And today, that's done with DNA testing.

Mostly, yes.

It's far more powerful and definitive than the older enzyme assays.

The second route is fetal analysis or prenatal diagnosis.

The first widely used technique was amniocentesis.

Where you take a sample of the amniotic fluid which has fetal cells in it.

But this is done later in the pregnancy.

Usually after week 14.

And then the cells have to be cultured for weeks which takes time.

It's a great test but it's slow and carries a small risk.

The alternative is chorionic villus sampling or CVS.

CVS has the big advantage of being done much earlier.

Between weeks 8 and 12.

You sample a piece of the chorion which is embryonic tissue from the placenta.

And the huge advantage there is timing.

The results are much faster.

Yes.

No cell culture is needed.

But it does carry a slightly higher risk of fetal loss than amnio.

And a slightly higher risk of an inaccurate diagnosis.

It's a trade -off.

A trade -off between the medical risks and the benefit of that early accurate genetic information.

This deep dive has really traced the journey of genetics.

From abstract principles to the absolute reality of molecular instruction.

We started with the newborn screen and that question.

How does the blueprint become the machinery?

We saw how Archibald Garrett all alone deduced the principle of the inborn error of metabolism.

Then came Beadle and Tatum who rigorously proved it with bread mold and clever logic establishing the one gene one enzyme hypothesis.

Which we then refined to the more accurate one gene one polypeptide model.

We reviewed these devastating human diseases like PKU and Tay -Sachs, the enzyme deficiencies and then the structural protein defects like sickle cell anemia and cystic fibrosis.

And we saw how all of this knowledge empowers genetic counseling.

Giving us tools like carrier detection and fetal analysis to manage risk and provide choice.

So where does this leave us?

What's the final thought?

Well here's where the past connects to the future.

While a disease like Tay -Sachs has no cure and PKU treatment relies on diet, the molecular understanding we have gained is the absolute foundation for curing them.

Because we know the precise instruction that's broken.

We know the precise instruction.

Think back to that gut microbe, M.

smithy.

We know its genes control its metabolism and that might contribute to obesity.

The future of medicine isn't just about fixing our own genes.

It might be about developing drugs to manipulate the metabolome of the microbes inside us.

So we're moving toward a future of targeted interventions.

Exactly.

Drugs that correct the misfolding of the CFTR protein or gene therapies that replace the non -functional enzyme in Tay -Sachs.

The core understanding that the gene is the blueprint for the protein.

That is the molecular master key.

It's the only way we can open the door to managing and eventually curing these deepest of conditions.

A truly fascinating journey from a single drop of blood to the molecular core of our existence.

That concludes this deep dive.

Thank you for joining us.